Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:appearance |
3 to 5 days after fever
|
| gptkbp:associated_with |
gptkb:paramyxovirus
|
| gptkbp:caused_by |
measles virus
|
| gptkbp:characteristics |
maculopapular rash
|
| gptkbp:complications |
gptkb:healthcare_organization
gptkb:psychologist diarrhea |
| gptkbp:duration |
lifetime immunity after infection
long-lasting immunity after vaccination |
| gptkbp:end_of_life |
higher in immunocompromised individuals
higher in malnourished children |
| gptkbp:fledging_period |
4 days before to 4 days after rash
|
| gptkbp:global_presence |
over 140,000 deaths in 2018
|
| gptkbp:goal |
elimination of measles in many regions by 2020
global vaccination coverage increase |
| gptkbp:has_appearance |
inside the mouth
|
| gptkbp:healthcare |
surveillance systems
community education vaccination campaigns |
| gptkbp:historical_significance |
first described by Persian physician Rhazes
|
| https://www.w3.org/2000/01/rdf-schema#label |
measles
|
| gptkbp:incubation_period |
10 to 14 days
|
| gptkbp:is_documented_in |
9th century
|
| gptkbp:is_protected_by |
vaccination
|
| gptkbp:is_vulnerable_to |
gptkb:measles,_mumps,_and_rubella_vaccine_(MMR)
developed in the 1960s measles vaccine children at 12-15 months over 95% after two doses second dose at 4-6 years |
| gptkbp:region |
gptkb:Africa
gptkb:Europe Americas Eastern Mediterranean Western Pacific South-East Asia |
| gptkbp:risk_factor |
travel to endemic areas
lack of vaccination close contact with infected individuals |
| gptkbp:seed_dispersal |
single-stranded RNA
|
| gptkbp:significance |
early sign of measles
|
| gptkbp:social_responsibility |
clinical evaluation
serological testing PCR testing more common in winter and spring common in unvaccinated populations frequent in crowded areas |
| gptkbp:symptoms |
gptkb:Koplik_spots
cough fever sore throat runny nose rash high fever |
| gptkbp:transmission |
airborne droplets
|
| gptkbp:treatment |
supportive care
vitamin A supplementation |
| gptkbp:bfsParent |
gptkb:MMR_vaccine
gptkb:scarlet_fever gptkb:Koplik_spots gptkb:measles,_mumps,_and_rubella_vaccine_(MMR) gptkb:paramyxovirus |
| gptkbp:bfsLayer |
6
|